b'MRD TestsTest Name Indications for TestingFLT3 ITD MRD AssayIdentify tumor-specific markers for post-treatmentmonitoring Assay Type Monitor and evaluate disease recurrenceNext-Generation Sequencing (NGS)CLIA-validated assayMethod DescriptionTo track and identify previously detected FLT3 ITD mutations in post-treatment follow-up samples, a multiplex master mix targeting the juxtamembrane domain of the FLT3 gene is used to amplify DNA extracted from a patient sample.Next-generation sequencing of the PCR products is used to identify DNA sequences specific to previously identified mutations detected at diagnosis. Bioinformatics tools facilitate the detection of these specific sequences present at an allelic sensitivity level of 5x10 -5 .Interpretation TurnaroundSpecimenShippingSpecimen Time Requirements Conditions StabilityAn interpretive7 to 10 1-3 mL of peripheral Ambient or Cool; 2-8 C up report will bebusiness days blood in EDTA,do not freezeto 7 days priorissued indicating(peripheral blood orto testing whether FLT3 ITD0.25-1 mL of bone marrow bone marrow) MRD was detected in EDTA1 g of previously Ambient or frozen onisolated DNAdry ice (isolated DNA) LabPMM Services Catalog 2021|37'